|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Boswellia Serrata gum and Licorice extract are two nutritional agents that have pharmacological actions that could support the medical intervention for COVID-19. They have broad antiviral activity, anti-inflammatory, anti-lung injury, antibacterial activity, antithrombic formation, and immunomodulatory activity. The study will be conducted after January 18, 2017
Description: Conversion of RT-PCR indicates positive for novel coronavirus RNA to negativeMeasure: Increased number of people recovering from COVID-19 Time: 14 days
Description: Decrease number of patients that require respiratory support , management in the Intensive Care Unit (ICU) and need Mechanical Ventilation Support with endotracheal intubation.Measure: Decrease number of patients that require respiratory support , Time: 14 days
Description: Rapid recoveryMeasure: Decrease duration of hospital stay Time: 7 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports